Table 3 Characteristics of cohort studies
Citation | Country | Study period | Study design | Effect estimates | Study population (n) | Diagnosis criteria | |
|---|---|---|---|---|---|---|---|
Endometriosis | Autoimmune disease | ||||||
Nielsen et al. (2011) [28] | Denmark | 1977- 2007 | Retrospective cohort study; 12.1 years follow-up | SLE: SIR:1.6 (95%CI:1.2–2.1) SS: SIR:1.6 (95%CI:1.3–2.0) | Exposure: 37,661 | ICD8:codes 62,530–62539 ICD10: code group N80 | Medical records according to the ACR criteria |
Harris et al. (2016a) [25] | USA | 1989- 2011 | Prospective cohort study; 22 years follow-up | SLE: HR = 1.61 (95%CI:0.88–2.92) P < 0.05 RA: HR = 1.16 (95%CI:0.84–1.59) P < 0.05 | Exposure: 6434 Control: 108,019 | Self-reported laparoscopy | Medical records according to the ACR criteria |
Lin et al. (2020) [26] | Taiwan | 2000- 2012 | Retrospective cohort study; patients were followed until diagnosed with SLE, death(means = 8.1 years) | SLE: HR = 1.86 (95%CI:1.36–2.53) P < 0.0001 | Exposure: 17,779 Control: 17,779 | ICD-9-CM | Medical records according to board-certified rheumatologists |
Fan et al. (2021) [24] | Taiwan | 2000- 2011 | Retrospective cohort study; 12 years follow-upar | SLE: HR = 2.37 (95%CI:1.35–4.14) | Exposure: 16,758 Control: 16,758 | ICD-9-CM | ICD-9-CM |
Merlino et al. (2003) [33] | USA | 1986- 1997 | Prospective cohort study; 11 years follow-up | RA: RR = 1.59 (95%CI:0.82–3.08) | / | Self-reported physician diagnosis | Self-reported physician diagnosis |
Chen et al. (2020) | Taiwan | 2000- 2012 | Prospective cohort study; patients was followed until the appearance of RA, their removal from the NHIP, death, or the end of 2013 (means = 8.1 years) | RA: HR = 3.71 (95%CI: 2.91–5.73) P = 0.77 | Exposure: 17,913 Control: 17,913 | ICD-9-CM | ICD-9-CM |
Xue et al. (2020) | Taiwan | 2000- 2013 | Prospective cohort study; 13 years follow-up | RA: HR = 1.75 (95%CI: 1.27–2.41) P < 0.05 | Exposure: 14,463 Control: 14,463 | ICD-9-CM | ICD-9-CM |
Chao et al. (2022) [35] | Taiwan | 2000- 2012 | Retrospective cohort study | SS: HR = 1.45 (95%CI:1.27–1.65) P < 0.001 | Exposure: 14,733 Control: 58,932 | ICD-9-CM | ICD-9-CM |